

be examined together.

Applicants submit that the species requirements for "distinct segments" and "distinct number of conservative amino acids" is rendered moot, in light of the new claims.

REMARKS


New Claims 51-62 are pending in the application. Support for new Claims 51-58, relating to the generation of binding compounds, occurs on page 22 (lines 3-8), page 23 (lines 1-8), page 24 (lines 4-8), and elsewhere. Support for new Claims 51-58, relating to antibodies that bind to the complex of p40/IL-B30, but not to p40 alone or IL-B30 alone, occurs on page 14 (lines 12-14), and elsewhere. Support for new Claims 55-58 and 61-62, which relate to a fusion protein, occurs on page 9 (lines 9-13), page 18 (lines 15-18), Example IV (page 41), and elsewhere. Support for new Claims 54, 58, 60 and 62, occurs on page 14 (lines 30-31), page 33 (lines 33-34), page 34 (lines 5-23), and elsewhere. Support for new Claims 59-62 occurs on page 13 (lines 35-37), page 14 (lines 12-20), page 22 (lines 6-24), page 36 (lines 1-16), and in Example VII (page 42).

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.

Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected subject matter. Since Applicants have fully and completely responded to the Restriction Requirement and have made the required election, this application is now in order for early action.

Respectfully submitted,

Date: January 15, 2002

By: 
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

DNAX Research Institute
901 California Avenue
Palo Alto, California, 94304-1104
Tel. No. (650) 496-6400
Fax No.: (650) 496-1200